There are 2789 resources available
278P - Plasmid encoding p62/SQSTM1 administered in combination with CMF chemotherapy improves outcomes in metastatic triple-negative breast cancer patients
Presenter: Sergei Krasny
Session: ePoster Display
279P - Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)
Presenter: Cristina Saura Manich
Session: ePoster Display
280P - Intracranial activity of trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients with active brain metastases: Results from the first stage of the phase II TUXEDO-1 trial
Presenter: Rupert Bartsch
Session: ePoster Display
126P - Effects of GnRHa on ovarian function against chemotherapy-induced gonadotoxicity in premenopausal women with breast cancer in China: A prospective randomized controlled trial (EGOFACT)
Presenter: Xiangyun Zong
Session: ePoster Display
192P - Neoadjuvant chemotherapy (NACT) for estrogen and HER2 normal breast cancer (TNBC) in Denmark
Presenter: William Thomassen
Session: ePoster Display
203P - Randomized study of single-agent metronomic versus weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with HR+/HER2- advanced breast cancer
Presenter: Marina Cazzaniga
Session: ePoster Display
191P - Real-world data (RWD) on the long-term outcomes of the addition of carboplatin to standard neoadjuvant chemotherapy in triple-negative stage I-III breast cancer
Presenter: Hassan Shahryar Sheikh
Session: ePoster Display
193P - Adjuvant endocrine therapy in patients with breast cancer: Relationship between side effects, quality of life and treatment adherence
Presenter: Alda Tavares
Session: ePoster Display
194P - Stromal tumor-infiltrating lymphocyte scores in core needle biopsy and its correlation to complete pathological response to neoadjuvant systemic therapy
Presenter: Klara Gersak
Session: ePoster Display